SCHEMBL2800716

SCHEMBL2800716

CCCCCC=CCC=CCC=CCC=CCCCCC(O)CN

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.51
KDM4E B2RXH2 3/20 0.50
NFKB1 P19838 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
SOAT1 P35610 1/20 0.50
FFAR1 O14842 3/20 0.49
FFAR4 Q5NUL3 1/20 0.49
PPARG P37231 3/20 0.47
PPARD Q03181 2/20 0.47
PPARA Q07869 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
MEN1 O00255 1/20 0.47
USP2 O75604 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAPT P10636 1/20 0.47
HSPD1 P10809 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28254032 1.00 CNR1 (0.51) CNR1KDM4ENFKB1NFKB2RELA
SCHEMBL27170370 0.98 KDM4E (0.53) CNR1KDM4ENFKB1NFKB2RELA
SCHEMBL31254100 0.98 KDM4E (0.53) CNR1KDM4ENFKB1NFKB2RELA
SCHEMBL10526321 0.93 FFAR1 (0.55) SOAT1FFAR1FFAR4MEN1ALDH1A1
SCHEMBL29131470 0.93 FFAR1 (0.55) SOAT1FFAR1FFAR4MEN1ALDH1A1
SCHEMBL27987561 0.93 FFAR1 (0.55) SOAT1FFAR1FFAR4MEN1ALDH1A1
SCHEMBL4602415 0.93 FFAR1 (0.55) SOAT1FFAR1FFAR4MEN1ALDH1A1
SCHEMBL4616055 0.93 FFAR1 (0.55) SOAT1FFAR1FFAR4MEN1ALDH1A1
SCHEMBL13371693 0.89 NFKB1 (0.55) CNR1KDM4ENFKB1NFKB2RELA
SCHEMBL17743969 0.89 NFKB1 (0.55) CNR1KDM4ENFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116835903-B Shrinkage-reducing alkali-free liquid accelerator and preparation method thereof 陕西科之杰新材料有限公司 2026-05-19 CN claimed
CN-118284419-A Methods of treating post-traumatic stress disorder 杰资制药爱尔兰有限公司 2024-07-02 CN claimed
CN-117957234-A Thienopyrrole compounds 吉利德科学公司 2024-04-30 CN claimed
CN-117120450-A Thienopyrrole compounds 吉利德科学公司 2023-11-24 CN claimed
CN-117069411-A Multi-ring structure shrinkage reducing agent, alkali-free liquid accelerator and preparation method thereof 陕西科之杰新材料有限公司 2023-11-17 CN claimed
CN-116835903-A Shrinkage-reducing alkali-free liquid accelerator and preparation method thereof 陕西科之杰新材料有限公司 2023-10-03 CN claimed
CN-116783202-A Thienopyrrole compounds 吉利德科学公司 2023-09-19 CN claimed
CN-116835903-B Shrinkage-reducing alkali-free liquid accelerator and preparation method thereof 陕西科之杰新材料有限公司 2026-05-19 CN disclosed
US-20260102502-A1 CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY UNIV JOHNS HOPKINS (US) 2026-04-16 US disclosed
EP-4577247-A1 CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY The Johns Hopkins University (US) 2025-07-02 EP disclosed
EP-4003384-B1 AN EXTRACT FROM CANNABIS AND PEGANUM T C ERCIYES UNIV (TR) 2025-06-25 EP disclosed
WO-2025108106-A1 COMPOUND CONTAINING QUINOLINONE SKELETON AND USE THEREOF 中国药科大学 2025-05-30 WO disclosed
CN-119881144-A Method for extracting and detecting lipid in liquid milk raw milk 上海市质量监督检验技术研究院 2025-04-25 CN disclosed
WO-2007030697-A2 MODULATION OF NEUROGENESIS BY HDAC INHIBITION BRAINCELLS, INC. (US) 2007-03-15 WO disclosed
WO-2007025177-A2 NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION BRAINCELLS, INC. (US) 2007-03-01 WO disclosed
US-20070049576-A1 NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION BRAINCELLS, INC. (US) 2007-03-01 US disclosed
WO-2006133926-A1 PYRAZOLE DERIVATES AS CANNABINOID RECEPTOR MODULATORS CAREX SA (FR) 2006-12-21 WO disclosed
WO-2005113600-A2 METHODS FOR THE CONTROL, TREATMENT AND MANAGEMENT OF OBESITY HAPTOGEN LTD (GB) 2005-12-01 WO disclosed
US-20040132819-A1 Appetite control method ABBOTT LABORATORIES 2004-07-08 US disclosed
WO-2004012727-A1 COMPOSITIONS COMPRISING POLYSATURATED FATTY ACID (PUFAS) FOR THE CONTROL OF APPETITE AND BODY WEIGHT MANAGEMENT ABBOTT LABORATORIES (US) 2004-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260102502-A1 CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY CNR1, CNR2, GPR18 CNR1 1/4885KDM4E 1372/4885NFKB1 4295/4885
US-20070049576-A1 NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION CHRNB2, CHAT, CHRNB4 CNR1 198/4885KDM4E 2095/4885NFKB1 2613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.